RecruitingNot ApplicableNCT06731049

Comparison of the Effectiveness of Treadmill-Based Walking and Dual-Task Walking Training in Alzheimer's Disease

Comparison of the Effects of Treadmill-Based Walking and Dual-Task Walking Training on Activity and Cognition in Alzheimer's Disease


Sponsor

Istanbul University - Cerrahpasa

Enrollment

46 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Alzheimer's disease is a neurodegenerative condition that affects both cognitive and motor functions, making daily life activities more challenging. Motor functions, especially walking and balance, begin to deteriorate early in the disease and progress in parallel with cognitive decline. Dual-task performance, which refers to the ability to perform both motor and cognitive tasks simultaneously, significantly decreases in individuals with Alzheimer's disease. Current studies suggest that dual-task exercises can improve both cognitive and motor functions. In this context, treadmill-based dual-task training emerges as a promising approach to mitigate the effects of Alzheimer's disease. The study hypothesizes that treadmill-based dual-task training will have more positive effects on motor and cognitive parameters compared to treadmill exercise alone in individuals with Alzheimer's disease. The main research question of this study is whether treadmill-based dual-task exercise training, designed with progressively more challenging cognitive and motor tasks and tailored to the individual, results in significant improvements in motor and cognitive parameters, as well as daily living activities and dual-task performance, compared to a group that only undergoes treadmill exercise.


Eligibility

Min Age: 65 YearsMax Age: 85 Years

Inclusion Criteria5

  • Diagnosis of Alzheimer's disease according to the NINCDS-ADRDA criteria by a neurologist,
  • In the early or middle stages of the disease according to the Clinical Dementia Rating Scale (CDR),
  • Receiving medical treatment for Alzheimer's disease (e.g., cholinesterase inhibitors or memantine) for at least the past month,
  • Able to walk at least 400 meters in the 6-Minute Walk Test, indicating functional mobility,
  • Able to read and understand instructions given in Turkish.

Exclusion Criteria6

  • Having Lewy body dementia, frontotemporal dementia, or other types of dementia
  • Participating in a structured exercise program within the 6 months prior to starting the study
  • Having pulmonary, neurological, musculoskeletal, or rheumatological diseases that hinder walking
  • Having an unstable medical condition (e.g., uncontrolled diabetes or hypertension, deep vein thrombosis, etc.)
  • Having visual or auditory impairments that make communication difficult
  • Having behavioral problems that make participation in exercise difficult

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTreadmill-based Training Group

The walking speed will start at 75% of the walking speed calculated from the 10-meter Walk Test at normal walking pace, and the treadmill training will begin at this speed. Every two weeks, the speed will increase by 5%, and by the end of the 8th week, it will reach 100% of the normal walking speed. The aim of gradually increasing the walking speed is to progressively make the motor component of the exercise more challenging. Throughout the 8 weeks, a body weight support system will be used, and the support from the treadmill bar will be gradually reduced.

OTHERDual-Task Treadmill-based Training Group

In the Dual-Task Treadmill-based Training Group, the same walking training protocol as the Treadmill Training Group will be applied with added second tasks to create a dual-task walking protocol. The second tasks will consist of both cognitive and motor tasks. The difficulty of the tasks and the total duration of the dual-task training will be increased over time.


Locations(1)

İstanbul University-Cerrahpaşa

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06731049


Related Trials